ctDNA MRD+
1 drugsPredictive biomarker for patient selection in 6 indications
1
Approved Drugs
6
Indications
1
Companies
ctDNA MRD+ is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 6 indications including Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma. Explore the targeted therapies, indications, testing methods, and companies developing ctDNA MRD+ drugs below.
Search ctDNA MRD+ Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting ctDNA MRD+
| Drug | Company | Therapeutic Area |
|---|---|---|
| TECENTRIQ | Roche | Oncology |
ctDNA MRD+ Indications
Non-Small Cell Lung Cancer Small Cell Lung Cancer Hepatocellular Carcinoma Melanoma Alveolar Soft Part Sarcoma Muscle Invasive Bladder Cancer